SOGC CLINICAL PRACTICE GUIDELINEVulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis
Section snippets
Summary Statements
- 1.
Vulvovaginal candidiasis affects 75% of women at least once. Topical and oral antifungal azole medications are equally effective. (I)
- 2.
Recurrent vulvovaginal candidiasis is defined as 4 or more episodes per year. (II-2)
- 3.
Trichomonas vaginalis is a common non-viral sexually transmitted infection that is best detected by antigen testing using vaginal swabs collected and evaluated by immunoassay or nucleic acid amplification test. (II-2)
- 4.
Cure rates are equal at up to 88% for trichomoniasis treated with
Recommendations
- 1.
Following initial therapy, treatment success of recurrent vulvovaginal candidiasis is enhanced by maintenance of weekly oral fluconazole for up to 6 months. (II-2A)
- 2.
Symptomatic vulvovaginal candidiasis treated with topical azoles may require longer courses of therapy to be resolved. (1-A)
- 3.
Test of cure following treatment of trichomoniasis with oral metronidazole is not recommended. (I-D)
- 4.
Higher-dose therapy may be needed for treatment-resistant cases of trichomoniasis. (I-A)
- 5.
In pregnancy, treatment
VULVOVAGINAL CANDIDIASIS
Vulvovaginal candidiasis is a very common condition that affects up to 75% of women at least once in their lifetime.1 Risk factors for VVC include sexual activity, recent antibiotic use, pregnancy, and immunosuppression from such conditions as poorly controlled HIV infection or diabetes.2., 3.
The Organism
T. vaginalis is an anaerobic parasitic protozoan flagellated organism that adheres to epithelial cells of the urogenital tract. For the most part, infection is limited to the genitourinary tract. With infection, the condition is referred to as Trichomoniasis.
The Disease
The prevalence of T. vaginalis in the United States is reported as 3.1% among women of reproductive age (14–49).20 Globally, it is considered the most common non-viral STI, with an estimated 170 million cases reported annually.21 It is not
The Organism
Normal vaginal flora consists of both aerobic and anaerobic bacteria, with Lactobacillus species being the predominant microorganisms and accounting for greater than 95% of all bacteria present.41., 42. Lactobacilli are believed to provide defense against infection in part by maintaining an acidic pH in the vagina and ensuring hydrogen peroxide is present in the environment. In contrast, bacterial vaginosis is a polymicrobial syndrome resulting in a decreased concentration of lactobacilli and
REFERENCES (76)
Vulvovaginal candidosis
Lancet
(2007)- et al.
Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole
Am J Obstet Gynecol
(2001) - et al.
Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole in the treatment of recurrent vulvovaginal candidiasis
Am J Obstet Gynecol
(2001) - et al.
Teratogenic effects of vaginal boric acid treatment during pregnancy
Int J Gynaecol Obstet
(2006) Trichomonas vaginalis vaginitis. A comparative study of treatment and incidence
Am J Obstet Gyn
(1938)- et al.
Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women
Am J Obstet Gynecol
(2009) - et al.
Trichomonas vaginalis and amplification of HIV-1 transmission
Lancet
(1998) - et al.
Safety of metronidazole in pregnancy: a meta-analysis
Am J Obstet Gynecol
(1995) Bacterial vaginosis: emphasis on upper genital tract complications
Obstet Gynecol Clin North Am
(1989)Diagnostic microbiology of bacterial vaginosis
Am J Obstet Gynecol
(1993)
Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy
Am J Obstet Gynecol
Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis
Am J Obstet Gynecol
Plasma cell endometritis in women with symptomatic bacterial vaginosis
Obstet Gynecol
Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease
Obstet Gynecol
Bacterial colonization of the vagina during pregnancy in four ethnic groups
Am J Obstet Gynecol
Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations
Am J Med
Tinidazole vs metronidazole for the treatment of bacterial vaginosis
Am J Obstet Gynecol
Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis
Am J Obstet Gynecol
Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo- controlled study
Am J Obstet Gynecol
Efficacy and safety of vitamin C vaginal tablets in the treatment of non-specific vaginitis. A randomised, double blind, placebo-controlled trial
Eur J Ob Gyn Reprod Biol
Money DM; Society of Obstetricians and Gynaecologists of Canada Infectious Diseases Committee. Screening and management of bacterial vaginosis in pregnancy. SOGC Clinical Practice Guideline, No. 211, August 2008
J Obstet Gynaecol Can
Management of patients with recurrent vulvovaginal candidiasis
Drugs
HIV Epidemiology Research Study (HERS) Group. Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women
J Infect Dis
Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes
BMC Infect Dis
Candidosis of the fenitalia
Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection
J Clin Microbiol
Canadian guidelines on sexually transmitted infections—updated January 2010
Genital mycotic infections in patients with diabetes
Postgrad Med
The occurrence of vaginal infections among HIV-infected and high-risk uninfected women: longitudinal findings of the Women’s Interagency HIV Study
J Aquir Immune Defic Syndr
Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics
J Clin Microbiol
Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)
Cochrane Database Syst Rev.
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis
N Engl J Med
Infectious Diseases Society of America. Guidelines for treatment of candidiasis
Clin Infect Dis
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy
N Engl J Med
Intermittent prophylactic treatment of recurrent vaginal candidiasis by postmenopausal application of a 500 mg clotrimazole vaginal tablet
Genitourin Med
Use of oral fluconazole during pregnancy and the risk of birth defects
N Eng J Med
The prevalence of Trichomonas vaginalis infection among reproductive age women in the United States, 2001-2004
Clin Infect Dis
Global prevalence and incidence estimates of selected curable STDs
Sex Transm Dis
Cited by (101)
Managing recurrent vulvovaginal thrush from patient and healthcare professional perspectives: A systematic review and thematic synthesis
2024, Patient Education and CounselingEffectivity and efficacy probiotics for Bacterial Vaginosis treatments: Meta-analysis
2022, Infectious Disease ModellingCitation Excerpt :These are in accordance with existing research, stating that antibiotics without probiotics have a high recurrence rate (Hillier et al., 2017; Nyirjesy & Schwebke, 2018; Schwebke et al., 2017). Metronidazole is the recommended treatment option for BV (van Schalkwyk et al., 2015; Workowski et al., 2015). However, its recurrence rate is reported to be 21.2%–25.5% compared to probiotics which are 10.6%–11% (Faught & Reyes, 2019).
Insights and advances in recurrent vulvovaginal candidiasis
2023, PLoS Pathogens
This clinical practice guideline has been prepared by the Infectious Diseases Committee, reviewed by the CANPAGO and Family Physician Advisory Committees, and approved by the Executive and Board of the Society of Obstetricians and Gynaecologists of Canada.
Disclosure statements have been received from all contributors.
This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be reproduced in any form without prior written permission of the SOGC.